Vividion Therapeutics, Inc.

Happy #NationalInternDay! Summer in San Diego means blue skies and new horizons for our student interns at Vividion. We’ve enjoyed getting to know these future stars of science and giving them an inside look at the world of drug discovery and development. Check out photos from one recent event, where the interns joined with their summer mentors for a fun – and highly competitive – Lego-building race.

Vividion is expanding our presence in San Diego!   We’re excited to unveil our future corporate headquarters and research and development center, where we will continue leading innovation in chemoproteomics-enabled drug discovery and advancing our expansive portfolio of clinical and preclinical programs.    Read more in today’s news: https://bit.ly/4dbeJ4f

WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI), which occurs in certain cancer subtypes. At the Cancer Molecular Therapeutics Research Association 2024 Annual Meeting, Vividion Chief Scientific Officer Matt Patricelli will present our chemoproteomics approach that led to the discovery of a novel covalent allosteric inhibitor of WRN. One of the first inhibitors to target WRN to make it to the clinic, it is now being evaluated in a Roche-sponsored Phase 1 first-in-human clinical trial. #CMTRA #CancerResearch

We wish everyone a #HappyPride! Join us in celebrating the accomplishments of the LGBTQIA+ community and continuing each day forward to foster an inclusive society for all.    #Pride2024

Vividion Chief Scientific Officer Matt Patricelli will present at the American Association for Cancer Research (AACR) special conference exploring synthetic vulnerability as a strategy enabling therapeutic development for difficult-to-treat cancers, being held June 10-13 in Montreal. His talk will focus on the discovery of VVD-133214 (also known as RO7589831), a covalent allosteric inhibitor of Werner helicase (WRN), which is currently being evaluated in a Roche-sponsored Phase 1 first-in-human clinical trial.

It’s #BIO2024 Week in San Diego! We’re excited to connect with industry peers and collaborators in Vividion’s home city. Join us Wednesday, when our CEO Aleksandra Rizo will share her perspective on pioneering biotech innovation. More details: https://lnkd.in/ehdN3nJv   

By collaborating with partners like Roche, we are able to harness our collective expertise to accelerate innovation and therapeutic development. Through our work together, one of the first WRN inhibitors is now in the clinic with the potential to be a first-in-class medicine for patients with cancers with microsatellite instability.

As we look ahead to #BIO2024, we’re taking a look back at this interview with our CEO Aleksandra Rizo in Nature Reviews Drug Discovery, which provides a wide-ranging look at Vividion’s powerful chemoproteomics discovery platform and our progress into clinical trials. It’s a must-read ahead of next week’s event. https://lnkd.in/g8yWKTu6 (subscriber access required) 

We are looking forward to this year’s BIO International Convention, happening June 3-6 in San Diego. Vividion CEO Aleksandra Rizo will be part of an all-star panel sponsored by Bayer focused on pushing the boundaries of innovation as a first-in-class biotech. Learn more about this exciting panel and make plans to attend: https://lnkd.in/ehdN3nJv   #BIO2024

We’re thrilled to see our President and CEO Aleksandra Rizo named one of In Vivo’s 2024 Rising Leaders to watch in the life sciences industry. Her passion for developing novel medicines for patients in need is an inspiration to our whole organization. https://lnkd.in/eCaKvxQd Speaking to In Vivo, Aleks said, “It’s part of my personality to take on new challenges and I enjoy learning and riding the wave.” Read more to learn about how Vividion, with Aleks at the helm, has translated our pioneering drug discovery work into a pipeline of clinical-stage small molecule therapeutics. https://lnkd.in/e5Z3qRia